Gene and cell therapy competition is shifting beyond efficacy. Durability, safety, long-term evidence and commercialization are emerging as key differentiators across advanced therapies.
Coverage Period: Sep 1–Oct 6, 2026
Introduction
The defining story of this period was that gene and cell therapy competition is shifting from proving that one-time therapies can work to proving that they can deliver durable, safe and commercially credible value over time.
That shift was visible across several modalities. Ultragenyx secured the first FDA approval for Sanfilippo syndrome Type A, Intellia moved an in vivo CRISPR therapy into Priority Review, Beacon reported pivotal gene therapy data in X-linked retinitis pigmentosa, and developers across oncology, ophthalmology and neurology presented multi-year follow-up. At the same time, autoimmune CAR-T safety events highlighted how quickly the risk-benefit equation changes outside cancer. Together, these developments show a field moving beyond technological validation toward a more demanding phase centered on durability, evidence quality, safety and execution.
Executive Summary
- Durability is becoming one of the most important measures of CGT value. Five-year CARVYKTI data in earlier-line multiple myeloma, three-year follow-up for surabgene lomparvovec in diabetic retinopathy and four-year Huntington’s disease data from uniQure reinforce the need to demonstrate sustained benefit well beyond the initial response window.
- Regulatory progress is validating multiple advanced therapy platforms. Ultragenyx secured approval for FAYUVI in MPS IIIA, Intellia’s lonvo-z entered FDA Priority Review with a March 2027 PDUFA date, and Beacon’s laru-zova met the primary endpoint in a pivotal XLRP trial. The strategic challenge is now shifting from proving regulatory feasibility to delivering commercially viable products.
- CGT is moving further into markets where chronic therapy already works. In HAE, diabetic retinopathy and autoimmune disease, the value proposition increasingly depends on replacing or reducing long-term treatment burden rather than simply addressing an absence of therapeutic options.
- Safety is becoming a sharper platform-level differentiator in autoimmune CAR-T. Kyverna reported durable miv-cel responses without high-grade CRS, ICANS or IEC-HS, while competing programs from Novartis and Bristol Myers Squibb encountered inflammatory safety events and enrollment disruption.
- The quality of long-term evidence is becoming more consequential. UniQure’s experience with changing external-control estimates in Huntington’s disease shows how comparator design, attrition and missing data can materially influence interpretation of durable treatment effects.
Watch the video summary
Strategic Perspectives on Gene and Cell Therapy: Emerging Trends Shaping Competition
Durability Is Becoming the Core Economic and Clinical Argument for One-Time Therapy
Recent data added several examples of advanced therapies maintaining benefit over multiple years, but the larger implication is that durability is becoming central to how CGT products will be valued.
Johnson & Johnson reported five-year follow-up from an early-line CARTITUDE-2 cohort in which 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy. In ophthalmology, REGENXBIO reported that six of 10 evaluable Dose Level 3 participants receiving surabgene lomparvovec achieved a greater than two-step DRSS improvement at three years without additional diabetic retinopathy treatment. UniQure, meanwhile, presented Huntington’s disease data extending to 48 months, with continued slowing on functional measures despite greater statistical uncertainty at the later timepoint.
These are different diseases, modalities and development stages, but they point to the same strategic issue. A one-time intervention has to justify its complexity and upfront cost by creating value over a much longer period than conventional therapies. The relevant comparison is therefore not just initial response. It is the cumulative burden of repeated treatment, monitoring, adherence and healthcare utilization that may be avoided if benefit persists.
Long-term data may also influence when therapies are used. The CARVYKTI findings strengthen the rationale for moving highly active cellular therapies earlier in myeloma, where patients may have a better opportunity to achieve prolonged treatment-free control. Similar logic could eventually apply in non-oncology diseases if earlier intervention preserves function or prevents irreversible progression.
The market implication is that durability may become one of the most commercially meaningful differentiators in CGT. Developers that can show sustained treatment-free intervals could build stronger clinical and payer arguments than competitors relying mainly on short-term efficacy.
The key uncertainty is that long-term evidence is often generated in small cohorts. The sector will need to distinguish genuine durability from results influenced by patient selection, attrition or limited numbers.
Gene and Cell Therapy Is Moving Into Markets Where Existing Therapy Raises the Competitive Bar
A second important signal is that advanced therapies are moving into diseases where patients already have effective treatment options.
Intellia’s lonvoguran ziclumeran illustrates this shift. Its BLA for hereditary angioedema was accepted with Priority Review after the Phase 3 HAELO study showed an 87% reduction in mean monthly attacks versus placebo, with 62% of treated patients attack-free and free from HAE therapy during the six-month efficacy evaluation period. If approved, lonvo-z would introduce a one-time gene-editing option into a market already served by chronic prophylactic therapies.
REGENXBIO’s diabetic retinopathy program presents a similar strategic challenge. The attraction of surabgene lomparvovec is not simply that it can improve retinal disease measures, but that a one-time in-office treatment could potentially reduce the need for repeated injections and ongoing intervention.
This changes what constitutes meaningful differentiation. In diseases with no available treatment, strong efficacy can establish a compelling clinical proposition. In markets with effective chronic therapy, CGT must deliver enough additional value in durability, convenience, disease modification or freedom from ongoing treatment to justify a more complex and less reversible intervention.
That may shape portfolio strategy across the sector. The most attractive future indications may not necessarily be the areas with the highest unmet need, but those where the cumulative economic and clinical burden of chronic therapy creates a strong rationale for a one-time alternative.
The market implication is that CGT companies entering established treatment markets will need to compete on relative value rather than technological novelty. Commercial positioning will depend heavily on how clearly a one-time therapy changes the long-term treatment experience.
The key uncertainty is the adoption threshold. Physicians and patients may be reluctant to exchange familiar, effective chronic therapy for an irreversible intervention unless the durability and safety advantage is clear.
CAR T Therapy in Autoimmune Disease Is Testing a New Risk-Benefit Balance
CAR T therapy in autoimmune disease generated one of the clearest strategic contrasts of the month.
Kyverna reported one-year data for mivocabtagene autoleucel in stiff person syndrome, including sustained improvements in mobility and 92% of patients remaining free from chronic immunotherapies. The company also reported continued benefit in generalized myasthenia gravis and emphasized that it had observed no high-grade CRS, ICANS or IEC-HS across more than 100 treated patients.
Those results became more significant because competing autoimmune CAR-T programs encountered safety problems. Novartis placed trials of rapcabtagene autoleucel on hold after severe IEC-HS events, including deaths, while Bristol Myers Squibb paused enrollment in trials of zolacabtagene autoleucel following inflammatory events.
The broader issue is not which company currently has the best safety profile. It is whether CAR-T platforms designed in oncology can be transferred into chronic autoimmune disease without redesigning the acceptable balance between potency and toxicity.
That balance is likely to be very different. In relapsed cancer, severe acute toxicity may be acceptable if the alternative is progressive disease with few remaining options. In autoimmune disease, patients may have years of life ahead of them and access to multiple chronic therapies. Even relatively rare severe events could therefore have an outsized impact on physician willingness to adopt treatment.
This could make manufacturing methods, expansion kinetics, construct design and immune-cell phenotype commercially relevant differentiators rather than purely technical attributes.
The market implication is that autoimmune CAR-T competition may be decided as much by therapeutic index as by efficacy. Platforms capable of producing durable immune reset with lower acute toxicity may be better positioned for broad non-oncology use.
The key uncertainty is whether the safety differences now emerging persist in larger datasets. Current patient numbers remain too small to determine whether they reflect true platform characteristics.
Regulatory Validation Is Shifting the Bottleneck Toward Commercial Execution
Recent developments also showed that regulatory success is becoming less exceptional across the gene and cell therapy landscape.
Ultragenyx received full FDA approval for FAYUVI in pediatric MPS IIIA, establishing the first approved therapy for Sanfilippo syndrome Type A and the company’s second gene therapy approval. Intellia advanced an in vivo CRISPR therapy into Priority Review, while Beacon’s pivotal VISTA trial in X-linked retinitis pigmentosa met its FDA-endorsed primary endpoint and supported plans for a rolling BLA.
These milestones matter individually, but their combined significance is that regulatory feasibility is becoming less of a binary question for the sector. Regulators are now assessing an increasingly diverse set of gene therapy, gene editing and cell therapy products across different diseases.
As regulatory precedent accumulates, platform novelty should become less valuable as a standalone competitive advantage. The harder questions will concern product execution: manufacturing consistency, treatment logistics, patient identification, treatment-center capacity, long-term monitoring and reimbursement.
FAYUVI makes this particularly visible. Approval shifts the challenge immediately toward getting eligible children diagnosed, referred to qualified centers, reimbursed and treated. Similar execution issues will become more important as gene and cell therapies move into larger populations.
The market implication is that operational capability may become a stronger competitive moat in CGT. Companies able to move patients efficiently through complex treatment pathways may capture more value than technically strong competitors with weaker delivery infrastructure.
The key uncertainty is whether healthcare systems can absorb larger numbers of one-time therapies without creating bottlenecks in treatment capacity, reimbursement or specialist access.
Gene and Cell Therapy Claims Will Require Stronger Long-Term Evidence
The final signal is that the quality of evidence supporting CGT claims will receive greater scrutiny as the sector matures.
UniQure’s Huntington’s disease program illustrates the challenge. At 36 months, the expanded high-dose dataset showed substantial slowing of disease progression versus an external control. At 48 months, the treatment effect on cUHDRS was smaller and no longer statistically significant against the updated comparator, while TFC continued to show a significant difference. The company argued that increasing missingness and survivor bias in the external-control dataset affected the comparison.
The important point for the CGT sector is not the outcome of that specific regulatory discussion. It is that long-term disease-modification claims can be highly sensitive to how comparator populations are constructed and how missing data are handled.
The same issue applies, to different degrees, to other long-term CGT datasets. Small cohorts showing three-, four- or five-year benefit are highly informative, but they cannot automatically answer questions about generalizability, late safety or the expected duration of effect across a broader commercial population.
As the field moves from rare disease into larger indications, regulators and payers may have more opportunity to request randomized evidence, active comparators and longer follow-up before accepting ambitious claims.
The market implication is that evidence-generation strategy is becoming a source of competitive advantage. Companies that invest early in robust longitudinal datasets, credible controls and transparent follow-up may be better positioned to defend value propositions and long-term efficacy claims.
The key uncertainty is how quickly evidentiary expectations will rise across different disease areas and whether accelerated or flexible regulatory pathways remain available as CGT expands beyond ultra-rare populations.
What We Are Watching Next in Gene and Cell Therapy Regulatory and Commercial Shifts
- Intellia’s March 10, 2027 PDUFA decision for lonvo-z will be an important test of both in vivo CRISPR regulation and the willingness of the HAE market to consider a one-time alternative to established prophylaxis.
- Beacon’s regulatory path for laru-zova will show how regulators assess the VISTA efficacy package and whether pivotal success can translate into the first approved treatment for XLRP.
- Autoimmune CAR-T safety differentiation will remain critical as Kyverna expands its dataset and competitors investigate inflammatory events. Larger patient numbers should clarify whether current safety differences are platform-related.
- Regulatory assessment of Huntington’s disease gene therapy may provide useful precedent for how external controls, missing longitudinal data and confirmatory evidence are handled in slowly progressive neurological disease.
- Commercial execution after approval will become increasingly important, particularly whether treatment-center capacity, patient identification and reimbursement can keep pace as advanced therapies target larger populations.
Key Takeaway: Gene and Cell Therapy Competition Is Shifting Toward Durability and Execution
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com